Stereotaxis to Highlight New Clinical Results and Automation Enhancements at Heart Rhythm 2016 in San Francisco May 4-7
May 04 2016 - 9:00AM
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative
technologies for the treatment of cardiac arrhythmias, announced
today that it will participate in the 37th Annual Heart Rhythm
Society (HRS) Scientific Sessions, May 4-7, 2016 in San Francisco.
During its 12th consecutive appearance at HRS, the Company will
share results of recently published clinical studies, new
technology enhancements, user experiences, and simulations of its
computer-controlled mapping and lesion formation capabilities at
Booth #1631.
“We are excited to bring together expert users of our remote
magnetic navigation platform and physicians searching for treatment
options that provide improved outcomes for complex cardiac
arrhythmias with a lower risk of adverse events and reduced fluoro
exposure to patients and physicians,” said William C. Mills,
Stereotaxis Chief Executive Officer. “Inspired by an abundance of
clinical data and empirical evidence, hospitals and physicians
worldwide are turning to our magnetic navigation and automation
solutions to strengthen their leadership in cardiac rhythm
management by simplifying and significantly enhancing therapy
delivery, especially in the complex clinical setting of ventricular
arrhythmias.”
In the HRS Rhythm Theatre on Friday, May 6, Stereotaxis will
host a lunch symposium featuring the latest insights and clinical
research by experienced users. Chaired by Dr. Mauricio Arruda
(University Hospitals Case Medical Center), who has completed more
than 1,200 procedures using the Niobe® remote magnetic navigation
system, the session will provide impressive clinical results of the
Niobe system in the treatment of ischemic and non-ischemic
ventricular tachycardia (VT) patients, and a discussion of the
Company’s multi-center, randomized, superiority study of VT
ablation outcomes. Guest speakers include Dr. Luigi Di Biase
(Albert Einstein College of Medicine at Montefiore Hospital), Dr.
Hiroshi Nakagawa (Oklahoma University Medical Center), and Dr.
Tamas Szili-Torok (Erasmus Medical Center).
Dr. Andrea Natale, Executive Medical Director of the Texas
Cardiac Arrhythmia Institute at St. David’s Medical Center,
recently spoke to EP Lab Digest about the value and potential of
remote magnetic navigation in electrophysiology for its May issue,
which will be available at HRS. In the article, Dr. Natale said,
“The people that have actually invested the time to become
proficient with remote magnetic navigation and its learning curve,
and addressed the differences between magnetic and manual
navigation, love this technology and find it difficult when
magnetic navigation cannot be used in a procedure.” Dr. Natale is
serving as global principal investigator for the Company’s
MAGNETIC-VT multi-center randomized study, which he believes could
establish remote magnetic navigation as the “gold standard” for
certain VT procedures.
In its exhibit space, Stereotaxis will highlight the latest
innovations to its Niobe system including the next generation user
interface, which includes new features such as improved catheter
tip-to-tissue contact confirmation based on bipolar impedance
information. During the HRS Rhythm Theatre on Friday, May 6, Dr.
Hiroshi Nakagawa will also share the development progress for the
lesion assessment and prediction tool called Magnetic Ablation
Index. Each of these software features can provide valuable
information to physicians while they are ablating tissue and also
furthers the ongoing efforts to fully automate the execution of
physician-defined ablation strategies. Finally, the Company will
unveil its newly developed, software-based simulation platform for
physician training, alongside a modeled beating heart phantom that
demonstrates the mechanics of its technologies in effective lesion
creation – paramount to acute and long-term success – within the
most difficult to reach and navigate regions of the heart.
About StereotaxisStereotaxis is a healthcare
technology and innovation leader in the development of robotic
cardiology instrument navigation systems designed to enhance the
treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. Over
100 issued patents support the Stereotaxis platform, which helps
physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and
productivity, and enhanced integration of procedural information.
Stereotaxis' core Epoch® Solution includes the Niobe® magnetic
navigation system, the Odyssey® portfolio of lab optimization,
networking and patient information management solutions, and the
Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received
regulatory clearance in the United States, European Union, Canada,
China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator,
V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter
advancement system have received clearance in the United States,
Canada, and the European Union. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe”, "estimate”, "project”, "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its continued listing on the NASDAQ
Capital Market, its ability to continue to manage expenses and cash
burn rate at sustainable levels, its ability to continue to work
with lenders to extend, repay or refinance indebtedness on
acceptable terms, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the
ability and willingness of customers to purchase its systems and
the timing of such purchases, competitive factors, changes
resulting from the recently enacted healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Company Contact:
Martin C. Stammer
Chief Financial Officer
314-678-6155
Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com